AlertEdge.io
Single-Ticker Trade Brief
GEHC — GE HealthCare Report Date: 2026-07-29 13:49 UTC  |  Sector: Health Care  |  Rating:
RISK DISCLAIMER: This is an momentum signal based on MACD and relative strength. Always validate before entering a position.
▲▲ Momentum Leader — MACD Cross + S&P 500 Outperformance

GEHC has a bullish MACD crossover on daily bars and is outperforming the S&P 500 by +15.36% over the past 63 trading days (GEHC +19.51% vs SPY +4.15%).

Ticker
GEHC
Entry Price
$71.06
vs S&P 500 (63d)
+15.36%
Ticker Return
+19.51%
Stop Loss
$66.08
TP1 Target
$78.52
TP2 Target
$83.5
Risk / Reward
1 : 1.5
Daily ATR stop
View GEHC Chart on TradingView

Key Price Levels

TP1 Target
$78.52
Breakout Level
$0
Entry
$71.06
Stop Loss
$66.08

Fundamentals

P/E Ratio
17.02518
EPS (TTM)
4.17
Dividend Yield
23.0%
52-Wk High
89.77
52-Wk Low
58.75
Beta
0.839

Deep Dive Analysis — Claude Sonnet

GEHC — GE HealthCare | Trade Brief

SETUP

GEHC gapped up roughly 10% today on earnings, closing near session highs at $71.06. The bar engulfs the prior range decisively, and MACD has crossed bullish from a depressed signal line, suggesting momentum is just beginning to inflect, not exhausted. The stock has outperformed SPY by over 15% in the past 63 days, and this earnings move extends that leadership. Price is attempting to reclaim the midpoint of its 52-week range (58.75 to 89.77), with room to run toward the upper half. The stop at $66.08 sits below the gap, giving the trade a logical structure.

CATALYSTS

Q2 EPS of $1.01 beat estimates by 10.6%, continuing a streak of four consecutive beats. Record orders are the headline driver, signaling strong forward demand for imaging and diagnostic equipment. Healthcare AI and hospital capital spending cycles are tailwinds. A lower beta of 0.84 offers relative stability if broader markets wobble. Multiple insider purchases across directors in May add a quiet but meaningful vote of confidence.

RISKS

Signal quality score of 50/100 is a real concern. This is a gap-and-go entry, meaning you are chasing a 10% single-day move with no base formation. Gap fills are common after earnings spikes, and a pullback to $64-65 would stop this trade out entirely. Next earnings are not until July 2026, removing a near-term catalyst. The 1:1.5 risk/reward is below the typical 1:2 minimum for high-conviction setups. Macro headwinds including hospital budget pressures or a rate-driven risk-off move could stall the recovery toward the 52-week high.

CONVICTION: Medium

Four consecutive earnings beats and record orders validate the fundamental story, but the 10% gap entry with a 50/100 signal score and sub-optimal risk/reward make this a wait-for-pullback setup rather than an aggressive chase.